ArticleClinical interventions in aging2025
Association Between Fibrinogen-to-Albumin Ratio and Long-Term Mortality in Senile Patients with Coronary Artery Disease: A Prospective 10-Year Follow-up Study.
Article in Clinical interventions in aging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The synergistic effect of fibrinogen and albumin on long-term mortality remains unclear in senile patients with coronary artery disease (CAD). This study aimed to evaluate the association between fibrinogen-to-albumin ratio (FAR) and 10-year mortality, and to develop a model to predict survival probability in senile patients with CAD. Methods: In total, 819 senile patients with CAD were enrolled on the basis of the China Geriatric Cardiovascular Comorbidity Study. Results: Compared with patients in the lowest FAR (FAR-Q1) group, the median overall survival (OS) was 2631 days, and patients in the highest FAR (FAR-Q4) group had the shortest OS, with a median of 311 days ( Conclusion: FAR was independently associated with long-term mortality, and a prognostic model based on FAR may aid risk stratification in senile patients with CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.